

13 October 2025

ASX Announcement

Bioxyne Announces Dual Listing on Frankfurt Stock Exchange

Bioxyne (ASX: BXN; FSE: PR8) ("the Company") is pleased to announce that its shares have commenced trading on the Frankfurt Stock Exchange ("FSE") under the ticker code PR8, as part of the company's strategy to engage with global investors. ASX remains Bioxyne's primary listing.

HIGHLIGHTS

- Bioxyne dual lists on Frankfurt Stock Exchange (FSE) under ticker code PR8
- The dual listing will enable European investors to easily trade Bioxyne shares without high transaction costs and foreign currency risks.
- The dual listing supports the Company's increased focus on Europe as evidenced by recent announcements on a €3.3 million (≈ A\$5.8 million) supply agreement with Adrex Pharmaceuticals and Farmakem d.o.o. for medicinal cannabis flower.
- The dual listing supports the company's global growth strategy and increased global investor interest in novel medicines (cannabis, MDMA, Psilocybin)
- The FSE, operated by Deutsche Börse AG, is one of the largest securities trading centres globally and the largest stock exchange in Germany.

The Frankfurt dual listing will broaden the Company's visibility and provide greater access to European investors.

Bioxyne is also pleased to announce the appointment of Dr Reuter IR as the company's European Investor Relations Specialist.

Dr. Reuter IR will assist Bioxyne to broaden its investor base in Europe - particularly across the DACH region (Germany, Austria, and Switzerland) and manage all European Investor Relations functions.

Sam Watson, CEO of Bioxyne, said *"Germany is a pivotal market for Bioxyne, and its subsidiary Breathe Life Sciences as it is the largest and fastest growing legal cannabis market in Europe, projected to surpass €1 billion in sales by 2026. Approximately 95% of the German market is focused on dried flower, which aligns with Breathe Life Sciences' core strength in processing and packaging GMP-certified cannabis flower. The dual listing and European engagement program will provide increased opportunities to communicate with investors and stakeholders."*

Dr Eva Reuter, CEO of Dr Reuter IR said, *"We look forward to working with Bioxyne - particularly at this exciting time for the company as European distributorships and*



collaborations are developed and progressed. Germany is one of the most advanced and rapidly growing medicinal cannabis markets in Europe, with a strong regulatory framework and increasing patient demand. Bioxyne's expertise in developing and delivering high-quality medicinal cannabis products makes the Company well suited to engage with German investors, who recognise both the medical importance and commercial potential of this sector."

Approved by the Board of Bioxyne Limited for release to the ASX.

For further information, please contact:

Bioxyne Limited

Investor Relations

Email: info@bioxyne.com

Phone: +61 2 9078 8180

Sam Watson

Chief Executive Officer



About Bioxyne and Breathe Life Sciences

About Bioxyne Limited

Bioxyne Limited is a licensed Australian pharmaceutical and healthcare company manufacturing and distributing novel medicines, health products and active pharmaceutical ingredients including medicinal cannabis, MDMA, and Psilocybin.

<https://bioxyne.com>

About Breathe Life Sciences (BLS)

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company’s corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, lifestyle products, functional mushrooms and nootropics, and prescription medicines in Australia.
- b) Contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe.
- c) Contract / white label manufacture of consumer health products for brands in Japan, UK and Europe in company-owned facilities.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®
 - **United Kingdom:** drwatsoncbd.com
 - **Japan:** nolcbn.com
 - **UK / EU:** breathelifesciences.com



- f) Export and supply of medicinal cannabis products and manufacturing services to UK and European markets.

Corporate: bioxyne.com

Australia: bls.com.au

International: breathelifesciences.com

For personal use only

